Strong brands for current trends – cannabidiol
13. August 2020
Intensive research on cannabis-based medicines began 20 years ago, and in Germany a cannabis extract was approved under pharmaceutical law for the first time in 2011.
More information can be found in the linked specialist article, which deals with the collected performance data and the unique characteristics of MIGLYOL® 812 N in comparison with other typical carrier oils in CBD tinctures. If you have any further questions, please contact Robert Radsziwil at email@example.com.
Robert Radsziwill joined IOI Oleo GmbH in 2019 as Sales Manager Europe in the Pharma division. Prior to joining IOI Oleo Pharma, Robert held technical and commercial roles in sales and product management for nine years at a supplier of raw materials to the Pharmaceutical and Medical Device industry. Through his experience with materials for pharmaceutical use and medical devices, Robert has contributed to the successful initiation and completion of new product development projects with industrial and academic partners in the Healthcare sector. Understanding, ranking and navigating technical, functional and regulatory concerns are paramount for him during early project ideation and material selection to ensure success for all project participants. Robert earned his diploma degree in Business Chemistry at the Westfälische-Wilhelms-University of Münster and has focused ever since on those disciplinary interfaces where technical and commercial minds join forces to innovate and improve the status quo.